Company profile
Enveric Biosciences, Inc.
NASDAQ: ENVB · Healthcare · Biotechnology
#470 of 1,422 Healthcare companies by revenue34th-percentile growth
EA Score
31DFH 33DQ 19GM 47SS 34
v0.1 · 65/100 weight · provisional
↑ net margin, operating margin · ↓ return on equity, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.8M
Employees
6
as of 2026-08-26
Market cap
$871.6k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$39.9M$39.9M2019
Net income-$8.8M-$8.8M2025
Operating income-$8.8M-$8.8M2025
Total assets$5.1M$5.1M2025
Liabilities$4.0M$4.0M2022
Equity$4.2M$4.2M2025
Revenue trend
FY2016 – FY2019 · USD
FY16
FY16
FY17
FY19
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Enveric Biosciences, Inc.’s revenue?
Enveric Biosciences, Inc. booked $39.9M in FY2019 revenue, contracting 7.2% year over year — slower than 66% of Healthcare companies we track, at a -22.0% net margin.
Peers · Healthcare
Alpha Teknova, Inc.58CVoyager Therapeutics, Inc.53DValeo Pharma Inc.——Big Tree Group, Inc.——Kymera Therapeutics, Inc.53DInterpace Biosciences, Inc.74BNeighbors
Collier →Key facts
CEOJoseph Edward Tucker
SectorHealthcare
IndustryBiotechnology
HeadquartersNaples, FL
ExchangeNASDAQ: ENVB
Employees6
IPO date2015-05-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.